Allogeneic stem cell transplantation (alloSCT) remains a valuable treatment option for fit patients with acute myeloid leukemia (AML), and the importance of measurable residual disease (MRD) monitoring in this malignancy is well established. Several clinicians and researchers are conducting trials to further evaluate how to improve outcomes for patients undergoing alloSCT.

In this podcast, you will hear from Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, and Christopher Hourigan, MD, DPhil, National Institutes of Health, Bethesda, MD, who discuss the important role of transplantation in AML, the value of pre-transplant MRD, and more. This discussion was filmed at the 18th International Symposium on Acute Leukemias (ISALXVIII), held in Munich, Germany.

The post The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD appeared first on VJHemOnc.